Umut VAROL, Ahmet ALACACİOĞLU, Halil TASKAYNATAN, Yuksel KUCUKZEYBEK, Yasar YILDIZ, Tarik SALMAN, Utku OFLAZOĞLU, Mustafa Oktay TARHAN, Yusuf UZUM, Seray SARAY

Prognostic role of pretreatment de ritis and neutrophil to lymphocyte ratio in neuroendocrine carcinoma patients (Izmir oncology group study)

Aim: Neutrophil/lymphocyte ratio (NLR) and AST/ALT ratio (De Ritis) were found to be prognostic in several cancers. So, our aim was to investigate the prognostic importance of these parameters and clinicopathological characteristics in patients with neuroendocrine carcinoma (NEC).Material and Methods: We retrospectively reviewed 101 NEC patients diagnosed in the last decade. The values of NLR and De Ritis were assessed at the time of diagnosis and their cut-off values were determined as 5 and 1.04 by receiver operating characteristics analysis. The prognostic role of high or low NLR and De Ritis according to these cut-off values and patient or tumor characteristicson clinical outcome was evaluated.Results: Among 101 patients, 77 were metastatic and 24 were early or locally advanced stage. Almost all patients were death at the time of data analysis (n:90). Twelve patients were treated with adjuvant chemotherapy or radiotherapy while 41 metastatic patients had received first-line chemotherapy. Median overall survival (OS) and progression free survival (PFS) was 7 months and 5 monthsin NLR low group and 6 months and 4 months in NLR high group (p:0.043, p:0.354), respectively. Median OS was 9 months in De Ritis low group and 5 months in De Ritis high group (p:0.004) while median PFS was 5 and 4 months in De Ritis low and high group of patients (p:0.077).Conclusion: Low De Ritis showed a strong and low NLR showed a weaker association with improved prognosis in patients with NEC.

PDF

___

1. Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (highgrade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010;39:799-800.
2. Glisson BS, Moran CA. Large-cell neuroendocrine carcinoma: controversies in diagnosis and treatment. J Natl Compr Canc Netw 2011;9:1122-9.
3. Sekihara K, Hishida T, Ikemura S, et al. The association of intravascular stromal cells with prognosis in highgrade neuroendocrine carcinoma of the lung. J Cancer Res Clin Oncol 2016;142:905-12.
4. Ohtaki Y, Kaira K, Atsumi J, et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung. Am J Transl Res 2018;10:3243-53.
5. Hermans BCM, Derks JL, Thunnissen E, et al. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). Lung Cancer 2019;130:179-86.
6. Casali C, Stefani A, Rossi G, et al. The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 2004;77:247-52.
7. Ryuge S, Sato Y, Jiang SX, et al. Prognostic impact of nestin expression in resected large cell neuroendocrine carcinoma of the lung. Lung Cancer 2012;77:415-20.
8. Aly RG, Rekhtman N, Li X, et al. Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. J Thorac Oncol 2019;14:1583- 93.
9. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013;24:152-60.
10. Tangjitgamol S, Ramirez PT, Sun CC, et al. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. Int J GynecolCancer 2005;15:646-56.
11. Siriaunkgul S, Utaipat U, Suwiwat S, et al. Prognostic value of HPV18 DNA viral load in patients with earlystage neuroendocrine carcinoma of the uterine cervix. Asian Pac J Cancer Prev 2012;13:3281-5.
12. Boo YJ, Park SS, Kim JH, et al. Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers. J Surg Oncol 2007;95:110-7.
13. Zhang Y, Chen Z, Bao Y, et al. Invasive neuroendocrine carcinoma of the breast: a prognostic research of 107 Chinese patients. Neoplasma 2013;60:215-22.
14. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
15. Lin EY, Pollard JW.Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 2004;90:2053- 8.
16. Zahorec R. Ratio of neutrophil to lymphocyte counts. Rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001;102:5- 14.
17. Proctor MJ, McMillan DC, Morrison DS, et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012;107:695-9.
18. Sarraf KM, Belcher E, Raevsky E, et al. Neutrophil/ lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009;137:425-8.
19. Takahashi Y, Masafumi Kawamura B, et al. Neutrophil– lymphocyte ratio as a prognostic marker for lung adenocarcinoma after complete resection. World J Surg. 2016;40:365-72.
20. An X, Ding P-R, Li Y-H, et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010;15:516-22.
21. Mallappa S, Sinha A, Gupta S, et al. Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer. Colorectal Dis 2013;15:323-8.
22. Duan J, Pan L, Yang M. Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer: A meta-analysis. Medicine (Baltimore) 2018;97:e13340.
23. Mellor KL, Powell AGMT, Lewis WG. Systematic Review and Meta-Analysis of the Prognostic Significance of Neutrophil-Lymphocyte Ratio (NLR) After R0 Gastrectomy for Cancer. J Gastrointest Cancer 2018;49:237-44.
24. Wei Y, Jiang YZ, Qian WH. Prognostic role of NLR in urinary cancers: a meta-analysis. PLoS One 2014;9:e92079.
25. Cho H, Hur HW, Kim SW, et al. Pretreatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009;58:15-23.
26. Okui M, Yamamichi T, Asakawa A, et al. Prognostic significance of neutrophil-lymphocyte ratios in large cell neuroendocrine carcinoma. Gen Thorac Cardiovasc Surg 2017;65:633-9.
27. De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis: the transaminase serum activities. 1957. Clin Chim Acta 2006;369:148-52.
28. Freis P, Graillot E, Rousset P, et al. Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers. Sci Rep 2017;7:40609.
29. Tan X, Xiao K, Liu W, et al H. Prognostic factors of distal cholangiocarcinoma after curative surgery: a series of 84 cases. Hepatogastroenterology 2013;60:1892-5.
30. Bezan A, Mrsic E, Krieger D, et al. The preoperative AST/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma. J. Urol 2015;194:30-5.
31. Lee H, Choi YH, Sung HH, et al. De Ritis Ratio (AST/ ALT) as a Significant Prognostic Factor in Patients With Upper Tract Urothelial Cancer Treated With Surgery. Clin Genitourin Cancer 2017;15:e379-e85.
32. Takenaka Y, Takemoto N, Yasui T, et al. Transaminase activity predicts survival in patients with head and neck cancer. PLoS One 2016;11:e0164057.
33. Chen SL, Li JP, Li LF, et al. Elevated Preoperative Serum Alanine Aminotransferase/Aspartate Aminotransferase (ALT/AST) Ratio Is Associated with Better Prognosis in Patients Undergoing Curative Treatment for Gastric Adenocarcinoma. Int J Mol Sci 2016;17.
34. Yang Q, Xu Z, Chen X, et al. Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis. Thorac Cancer 2019;10:751-60.
35. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006;24:70-6.